Item request has been placed!
×
Item request cannot be made.
×
Processing Request
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1099-1069 (Electronic) Linking ISSN: 02780232 NLM ISO Abbreviation: Hematol Oncol Subsets: MEDLINE
- Publication Information:
Original Publication: Oxford, England : Wiley-Blackwell, c1983-
- Subject Terms:
- Abstract:
Existing therapies for Sézary syndrome (SS) are limited in efficacy and in disease control, and patients have very poor prognosis. Here, we report a case report of a patient who has a 16-year history of SS and related treatments (both standard and experimental). In particular, two drugs, one conventional (gemcitabine) and one experimental (mogamulizumab), were able to induce long lasting response. Patient refused to undergo allogeneic stem cell transplantation. After eleven lines of therapeutic approaches, the patient is in very good partial response and free of therapy at the latest available follow-up.
(© 2019 John Wiley & Sons, Ltd.)
- Contributed Indexing:
Keywords: Sézary syndrome; experimental drugs; prolonged disease control
- Accession Number:
0 (Antibodies, Monoclonal, Humanized)
0W860991D6 (Deoxycytidine)
YI437801BE (mogamulizumab)
0 (Gemcitabine)
- Publication Date:
Date Created: 20190115 Date Completed: 20190507 Latest Revision: 20221207
- Publication Date:
20231215
- Accession Number:
10.1002/hon.2573
- Accession Number:
30637815
No Comments.